Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter H Hagedorn

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|August 15, 2019
Identifying Suitable Target Regions and Analyzing Off-Target Effects of Therapeutic OligonucleotidesLykke Pedersen, Peter H Hagedorn, Troels Koch
Physiologia Plantarum|March 23, 2004
Modelling NADH turnover in plant mitochondriaPeter H. Hagedorn, Henrik Flyvbjerg, Ian M. Møller
Nucleic Acids Research|November 11, 2017
RNase H sequence preferences influence antisense oligonucleotide efficiencyLukasz J Kielpinski, Peter H Hagedorn, Morten Lindow, et al.
Nucleic Acids Research|April 21, 2017
Managing the sequence-specificity of antisense oligonucleotides in drug discoveryPeter H Hagedorn, Bo R Hansen, Troels Koch, et al.
Molecular Therapy. Nucleic Acids|February 20, 2014
A Kinetic Model Explains Why Shorter and Less Affine Enzyme-recruiting Oligonucleotides Can Be More PotentLykke Pedersen, Peter H Hagedorn, Marie Wickström Lindholm, et al.
Nucleic Acids Research|February 5, 2019
RNase H sequence preferences influence antisense oligonucleotide efficiencyŁukasz J Kiełpiński, Peter H Hagedorn, Morten Lindow, et al.
Nucleic Acid Therapeutics|October 7, 2021
Characterization of <i>Escherichia coli</i> RNase H Discrimination of DNA Phosphorothioate StereoisomersŁukasz J Kiełpiński, Erik Daa Funder, Steffen Schmidt, et al.
Molecular Therapy. Nucleic Acids|January 18, 2020
Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical PropertiesNatalia Papargyri, Malene Pontoppidan, Mikael R Andersen, et al.
Biophysical Journal|June 14, 2005
Cell motility as persistent random motion: theories from experimentsDavid Selmeczi, Stephan Mosler, Peter H Hagedorn, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 17, 2004
Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetesFrancisco J Quintana, Peter H Hagedorn, Gad Elizur, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Methods in Molecular Biology (Clifton, N.J.)|August 15, 2019
Identifying Suitable Target Regions and Analyzing Off-Target Effects of Therapeutic OligonucleotidesLykke Pedersen, Peter H Hagedorn, Troels Koch
Physiologia Plantarum|March 23, 2004
Modelling NADH turnover in plant mitochondriaPeter H. Hagedorn, Henrik Flyvbjerg, Ian M. Møller
Nucleic Acids Research|November 11, 2017
RNase H sequence preferences influence antisense oligonucleotide efficiencyLukasz J Kielpinski, Peter H Hagedorn, Morten Lindow, et al.
Nucleic Acids Research|April 21, 2017
Managing the sequence-specificity of antisense oligonucleotides in drug discoveryPeter H Hagedorn, Bo R Hansen, Troels Koch, et al.
Molecular Therapy. Nucleic Acids|February 20, 2014
A Kinetic Model Explains Why Shorter and Less Affine Enzyme-recruiting Oligonucleotides Can Be More PotentLykke Pedersen, Peter H Hagedorn, Marie Wickström Lindholm, et al.
Nucleic Acids Research|February 5, 2019
RNase H sequence preferences influence antisense oligonucleotide efficiencyŁukasz J Kiełpiński, Peter H Hagedorn, Morten Lindow, et al.
Nucleic Acid Therapeutics|October 7, 2021
Characterization of <i>Escherichia coli</i> RNase H Discrimination of DNA Phosphorothioate StereoisomersŁukasz J Kiełpiński, Erik Daa Funder, Steffen Schmidt, et al.
Molecular Therapy. Nucleic Acids|January 18, 2020
Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical PropertiesNatalia Papargyri, Malene Pontoppidan, Mikael R Andersen, et al.
Biophysical Journal|June 14, 2005
Cell motility as persistent random motion: theories from experimentsDavid Selmeczi, Stephan Mosler, Peter H Hagedorn, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 17, 2004
Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetesFrancisco J Quintana, Peter H Hagedorn, Gad Elizur, et al.
Pageof 4